2-氯-6-苯并噻唑羧酸 | 3855-95-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并噻唑类
• 中文名称: 2-氯-6-苯并噻唑羧酸
• 中文别名: 2-氯苯并[d]噻唑-6-羧酸；2-氯苯并噻唑-6-甲酸
• 英文名称: 2-chlorobenzo[d]thiazole-6-carboxylic acid
• 英文别名: 2-Chlor-benzothiazol-6-carbonsaeure；2-Chloro-1,3-benzothiazole-6-carboxylic acid
• CAS: 3855-95-6
• 化学式: C₈H₄ClNO₂S
• mdl: MFCD08689736
• 分子量: 213.644
• InChiKey: QLAKWSXVXQRGDB-UHFFFAOYSA-N

物化性质

• 熔点：
  220-221
• 沸点：
  398.2±15.0 °C(Predicted)
• 密度：
  1.634

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  78.4
• 氢给体数：
  1
• 氢受体数：
  4

安全信息

• 危险等级：
  IRRITANT
• 危险品标志：
  Xi
• 海关编码：
  2934200090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335
• 储存条件：
  2-8°C

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 2-Chloro-1,3-benzothiazole-6-carboxylic acid
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 2-Chloro-1,3-benzothiazole-6-carboxylic acid
CAS number: 3855-95-6

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels, refrigerated.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C8H4ClNO2S
Molecular weight: 213.6

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen chloride, sulfur oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  2-氯-6-苯并噻唑羧酸 在 4-二甲氨基吡啶 、 sodium hexamethyldisilazane 作用下， 以 四氢呋喃 、 甲苯 、 叔丁醇 为溶剂， 反应 4.0h， 生成 tert-butyl 2-(2-ethoxy-2-oxoethyl)benzo[d]thiazole-6-carboxylate
  参考文献：
  名称：

  [EN] AMIDE, UREA OR SULFONE AMIDE LINKED BENZOTHIAZOLE INHIBITORS OF ENDOTHELIAL LIPASE
  [FR] INHIBITEURS DE LIPASE ENDOTHÉLIALE À BASE DE BENZOTHIAZOLE LIÉS À UNE AMINE, L'URÉE OU UN SULFONE AMIDE

  摘要：

  本发明提供了如规范中定义的Formula (I)的化合物，以及包含任何此类新化合物的组合物。这些化合物是内皮脂酶抑制剂，可用作药物。

  公开号：

  WO2014015088A1
• 作为产物：
  描述：

  二硫化碳 、 对氨基苯甲酸 生成 2-氯-6-苯并噻唑羧酸
  参考文献：
  名称：

  Bouanane,A. et al., Comptes Rendus des Seances de l'Academie des Sciences, Serie C: Sciences Chimiques, 1976, vol. 283, p. 319 - 321

  摘要：

  DOI：

文献信息

• FXR RECEPTOR MODULATOR, PREPARATION METHOD THEREFOR, AND USES THEREOF
  申请人：Guangzhou Henovcom Bioscience Co. Ltd.

  公开号：EP3401315A1

  公开（公告）日：2018-11-14

  The present disclosure disclosed a modulator of FXR receptor and preparation and use thereof, which relates to the technical filed of medicinal chemistry. The present disclosure provides a modulator of FXR receptor having a structural formula I or a pharmaceutically acceptable salt, stereoisomer, solvate or prodrug thereof, which can combine with FXR receptor (that is NR1H4) and be acted as a FXR agonist or a partial agonist for preventing and treating the disease mediated by FXR, such as chronic intrahepatic or extrahepatic cholestasis, hepatic fibrosis caused by chronic cholestasis or acute intrahepatic cholestasis, chronic hepatitis B, gallstone, hepatic carcinoma, colon cancer or intestinal inflammatory disease, etc. Specifically, for some chemical compounds, their EC50 for FXR agonist activity reach below 100nM, which show an excellent FXR agonist activity and an excellent prospect to provide a new pharmaceutical selection in clinical treatment for the disease mediated by FXR.

  本公开揭示了一种FXR受体调节剂及其制备和使用，涉及药物化学技术领域。本公开提供了一种具有结构式I或其药用可接受盐、立体异构体、溶剂合物或前药的FXR受体调节剂，可与FXR受体（即NR1H4）结合，并作为FXR激动剂或部分激动剂用于预防和治疗由FXR介导的疾病，如慢性肝内或肝外胆汁淤积、慢性胆汁淤积或急性肝内胆汁淤积引起的肝纤维化、慢性乙型肝炎、胆结石、肝癌、结肠癌或肠道炎症性疾病等。具体而言，对于某些化合物，它们的FXR激动剂活性的EC50值低于100nM，表现出优异的FXR激动剂活性，并有望为由FXR介导的疾病在临床治疗中提供新的药物选择。
• [EN] MANNOSE DERIVATIVES FOR TREATING BACTERIAL INFECTIONS<br/>[FR] DÉRIVÉS DE MANNOSE POUR LE TRAITEMENT D'INFECTIONS BACTÉRIENNES
  申请人：VERTEX PHARMA

  公开号：WO2013134415A1

  公开（公告）日：2013-09-12

  The present invention relates to compounds useful for the treatment or prevention of bacteria infections. These compounds have formula I: The invention also provides pharmaceutically acceptable compositions containing the compounds and methods of using the compositions in the treatment of bacteria infections. Finally, the invention provides processes for making compounds of the invention.

  本发明涉及用于治疗或预防细菌感染的化合物。这些化合物的公式为I：。发明还提供了包含这些化合物的药用可接受组合物，以及使用组合物治疗细菌感染的方法。最后，发明提供了制造本发明化合物的方法。
• ISOXAZOLE ANALOGS AS FXR AGONISTS AND METHODS OF USE THEREOF
  申请人：Enanta Pharmaceuticals, Inc.

  公开号：US20190194216A1

  公开（公告）日：2019-06-27

  The present invention provides compounds of Formula (I), and pharmaceutically acceptable salts thereof, as well as pharmaceutical compositions comprising these compounds and methods of using these compounds to prevent or treat FXR-mediated or TGR5-mediated diseases or conditions.

  本发明提供了式（I）的化合物及其药用盐，以及包含这些化合物的药物组合物，以及使用这些化合物预防或治疗FXR介导或TGR5介导的疾病或症状的方法。
• [EN] SULFONYL CONTAINING BENZOTHIAZOLE INHIBITORS OF ENDOTHELIAL LIPASE<br/>[FR] INHIBITEURS DE LIPASE ENDOTHÉLIALE DE TYPE BENZOTHIAZOLE CONTENANT UN SULFONYLE
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2014011513A1

  公开（公告）日：2014-01-16

  The present invention provides compounds of Formula (I) as defined in the specification and compositions comprising any of such novel compounds. These compounds are endothelial lipase inhibitors which may be used as medicaments.

  本发明提供了如规范中定义的化合物(I)的化合物，以及包含任何这种新化合物的组合物。这些化合物是内皮酯酶抑制剂，可用作药物。
• [EN] COMPOUNDS FOR AFFINITY CHROMATOGRAPHY AND FOR EXTENDING THE HALF-LIFE OF A THERAPEUTIC AGENT<br/>[FR] COMPOSÉS POUR CHROMATOGRAPHE D'AFFINITÉ, DESTINÉS À PROLONGER LA DEMI-VIE D'UN AGENT THÉRAPEUTIQUE
  申请人：GLAXOSMITHKLINE IP DEV LTD

  公开号：WO2015049651A1

  公开（公告）日：2015-04-09

  Compounds useful for affinity chromatography as presented, more particularly for use in affinity chromatography to purify serum albumin, especially human serum albumin (HSA) and fusion proteins thereof. Methods for extending the half-life of therapeutic agents are also presented, particularly therapeutic peptide agents and small molecules, such as by conjugation of compounds described herein to the therapeutic peptide or small molecule, which, upon administration, binds to HSA, thereby providing a prolonged release of the therapeutic agent.

  本文介绍了用于亲和层析的化合物，特别是用于亲和层析纯化血清白蛋白，尤其是人类血清白蛋白（HSA）和其融合蛋白的化合物。此外，本文还介绍了延长治疗剂半衰期的方法，特别是治疗性肽剂和小分子，例如将本文所述的化合物与治疗性肽剂或小分子结合，从而在给药时结合到HSA，从而提供治疗剂的长时间释放。